Amgen Inc. (NASDAQ: AMGN) reported its fourth-quarter financial results after the markets closed on Thursday. This biotech giant posted $2.89 in earnings per share (EPS) and $5.97 billion in revenue, versus consensus estimates that…
Benitec Biopharma saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for the treatment of ocular diseases.
AMAG Pharmaceuticals shares took a sharp turn down after the company reported top-line results from its most recent pharmacokinetic study.
Merck reported disappointing fourth-quarter financial results before the markets opened on Thursday.
Although this earnings season has been relatively positive, the Dow has stepped away from its 20,000 mark, and it seems the animal spirits powering this rally might not be as positive as they once…
Anthem released a better-than-expected earnings report before the markets opened on Wednesday, pushing shares to a new high.
Repealing Obamacare could cost up to 1.2 million U.S. jobs, and that is not a price that opponents are willing to pay yet.
In a new report, SunTrust Robinson Humphrey analysts are focused on upcoming catalysts for biotech stocks in their coverage universe.
Eli Lilly released a mixed fourth-quarter earnings report and offered full-year guidance before the markets opened on Tuesday.
When Pfizer reported its fourth-quarter financial results before the markets opened on Tuesday, earnings fell short of consensus estimates.
Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) saw its shares rise handily on Monday following positive top-line results from the company’s first-in-human pilot trial. Specifically, the trial is for the EyeGate Ocular Bandage Gel (OBG) for…
Rigel Pharmaceuticals shares saw a solid gain to kick off the week after the company gave an update on one of its clinical programs.
Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte.
Pulmatrix saw its shares take a sharp downturn on Monday morning after the company announced that it had entered into a definitive agreement with several investors for a direct offering valued up to roughly…
Novan saw its shares get absolutely crushed on Friday after the company reported results from its late-stage treatment of acne vulgaris. Analysts took this opportunity to weigh in on the future of this stock.
